Q3 2022 13F Holders as of 30 Sep 2022
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
56,078,244
-
Total 13F shares
-
21,451,239
-
Share change
-
-20,061
-
Total reported value
-
$36,251,000
-
Put/Call ratio
-
96%
-
Price per share
-
$1.69
-
Number of holders
-
54
-
Value change
-
-$315,195
-
Number of buys
-
16
-
Number of sells
-
30
Institutional Holders of Black Diamond Therapeutics, Inc. - Common Stock (BDTX) as of Q3 2022
As of 30 Sep 2022,
Black Diamond Therapeutics, Inc. - Common Stock (BDTX) was held by
54 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
21,451,239 shares.
The largest 10 holders included
Bellevue Group AG, NEA Management Company, LLC, RA CAPITAL MANAGEMENT, L.P., BOXER CAPITAL, LLC, Artal Group S.A., BlackRock Inc., K2 PRINCIPAL FUND, L.P., VANGUARD GROUP INC, Newtyn Management, LLC, and MILLENNIUM MANAGEMENT LLC.
This page lists
55
institutional shareholders reporting positions in this security
for the Q3 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.